These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 25437093)

  • 21. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis.
    Novakova L; Henricsson M; Björnson E; Axelsson M; Borén J; Rosenstein I; Lycke J; Cardell SL; Blomqvist M
    Mult Scler Relat Disord; 2023 Jun; 74():104705. PubMed ID: 37060853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
    Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
    Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
    Festoff BW; Li C; Woodhams B; Lynch S
    J Neurol Sci; 2012 Dec; 323(1-2):61-5. PubMed ID: 22967748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical Differences in Cerebrospinal Fluid between Secondary Progressive and Relapsing⁻Remitting Multiple Sclerosis.
    Herman S; Åkerfeldt T; Spjuth O; Burman J; Kultima K
    Cells; 2019 Jan; 8(2):. PubMed ID: 30678351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis.
    Brettschneider J; Maier M; Arda S; Claus A; Süssmuth SD; Kassubek J; Tumani H
    Mult Scler; 2005 Jun; 11(3):261-5. PubMed ID: 15957504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
    Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Leurs CE; Podlesniy P; Trullas R; Balk L; Steenwijk MD; Malekzadeh A; Piehl F; Uitdehaag BM; Killestein J; van Horssen J; Teunissen CE
    Mult Scler; 2018 Apr; 24(4):472-480. PubMed ID: 28294696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
    Teunissen CE; Koel-Simmelink MJ; Pham TV; Knol JC; Khalil M; Trentini A; Killestein J; Nielsen J; Vrenken H; Popescu V; Dijkstra CD; Jimenez CR
    Mult Scler; 2011 Jul; 17(7):838-50. PubMed ID: 21505015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Cristofanilli M; Gratch D; Pagano B; McDermott K; Huang J; Jian J; Bates D; Sadiq SA
    Mult Scler; 2017 Nov; 23(13):1707-1715. PubMed ID: 28273770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis.
    Emeršič A; Karikari TK; Kac PR; Gonzalez-Ortiz F; Dulewicz M; Ashton NJ; Brecl Jakob G; Horvat Ledinek A; Hanrieder J; Zetterberg H; Rot U; Čučnik S; Blennow K
    Mult Scler Relat Disord; 2024 Oct; 90():105801. PubMed ID: 39153429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
    Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?
    Abdelhak A; Junker A; Brettschneider J; Kassubek J; Ludolph AC; Otto M; Tumani H
    Int J Mol Sci; 2015 Jul; 16(8):17565-88. PubMed ID: 26263977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.
    Matsushita T; Tateishi T; Isobe N; Yonekawa T; Yamasaki R; Matsuse D; Murai H; Kira J
    PLoS One; 2013; 8(4):e61835. PubMed ID: 23637915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    Hjæresen S; Benedikz E; Sejbaek T; Axelsson M; Novakova L; Zhang M; Lycke J; Illes Z; Fex-Svenningsen Å
    J Neurol Sci; 2024 Feb; 457():122888. PubMed ID: 38278096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
    Komori M; Blake A; Greenwood M; Lin YC; Kosa P; Ghazali D; Winokur P; Natrajan M; Wuest SC; Romm E; Panackal AA; Williamson PR; Wu T; Bielekova B
    Ann Neurol; 2015 Jul; 78(1):3-20. PubMed ID: 25808056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.